Search terms included combinations of GLP-1 receptor agonist, semaglutide, liraglutide, tirzepatide, cutaneous side effects, dermatology, hidradenitis, psoriasis, bullous pemphigoid, facial aging, and plastic surgery. Of 260 articles initially identified, 155 were included on the basis of predefined eligibility criteria prioritizing randomized controlled trials, observational studies, systematic reviews, regulatory reports, and clinically relevant case series in adult populations
To date, the FDA has approved only liraglutide and semaglutide for weight loss in the pediatric population
And, you know, we interviewed some other women with different, substance use disorders
Pick one reliable option and keep it low-pressure